Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2007

View Archived Issues

Gilead Sciences reports progress of first quarter

Phase III studies show efficacy and safety of ferumoxytol iron replacement therapy

Recent GSK patent divulges novel therapeutic agent for atopic dermatitis

Improvements seen in type 2 diabetes patients given liraglutide

Etravirine demonstrates short-term efficacy in resistant HIV-1 infection

AstraZeneca to acquire MedImmune

Daiichi Sankyo to transfer all Daiichi Fine Chemical shares to Kyowa Hakko

Novel treatment options for HCV infection reported in recent GSK patents

Japanese submission for Glufast in combination with insulin sensitizer

R3 antibody shows efficacy in pancreatic cancer model

Phase IIa biomarker study investigates HF-0220 in mild to moderate Alzheimer's

Pharmion advances oral azacitidine in phase I

Actavis completes acquisition of Abrika

Enrollment completed in phase III study of Cerepro

Recent 3M and Obihiro University patents disclose new antiinfective agents

GGTase I inhibitor and prodrug profiled at AACR annual meeting

In vivo antitumor activity of novel anti-IGF-1R antibody reported by Schering-Plough

Nippon Shinyaku discontinues development of NS-9

FDA accepts Xcytrin NDA for filing

Approvable letter for bazedoxifene in prevention of postmenopausal osteoporosis

Maraviroc recommended for accelerated approval

Roche files Avastin and Xeloda submissions in Europe

New phase I trial studies NPI-0052 in multiple myeloma

Synosia in-licenses rufinamide for anxiety disorders and bipolar mood disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...